Disc Medicine Inc (IRON)
32.18
+0.26
(+0.81%)
USD |
NASDAQ |
May 17, 16:00
32.18
0.00 (0.00%)
After-Hours: 20:00
Disc Medicine Cash from Financing (TTM): 177.97M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 177.97M |
December 31, 2023 | 239.38M |
September 30, 2023 | 380.44M |
June 30, 2023 | 380.00M |
March 31, 2023 | 226.23M |
December 31, 2022 | 148.98M |
September 30, 2022 | -102.57M |
Date | Value |
---|---|
June 30, 2022 | -103.84M |
March 31, 2022 | -105.51M |
December 31, 2021 | 89.93M |
September 30, 2021 | 192.80M |
June 30, 2021 | 208.05M |
March 31, 2021 | 209.64M |
December 31, 2020 | 34.25M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-105.51M
Minimum
Mar 2022
380.44M
Maximum
Sep 2023
141.13M
Average
185.39M
Median
Cash from Financing (TTM) Benchmarks
ACADIA Pharmaceuticals Inc | 24.71M |
Alnylam Pharmaceuticals Inc | 154.67M |
Marinus Pharmaceuticals Inc | 27.06M |
Rocket Pharmaceuticals Inc | 191.24M |
Regenxbio Inc | 94.80M |